
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech is projected to have a firm value of $33B with an estimated price per share of $130 based on a discounted cash flow (DCF)-based valuation approach and projected financial metrics. The company's risks include negative data for certain drugs, slower market uptake, failure to advance other programs in a timely manner, and regulatory and commercial risks. However, recent data presented for BNT326 and pumitamig in multiple subgroups of NSCLC patients support the ongoing Phase 1b/2 trials evaluating their combination, thus providing a positive outlook on the company's progress in the oncology space.
Bears say
BioNTech is a Germany-based biotechnology company with a negative outlook due to concerns surrounding its pipeline and competitive risks. While the company's Phase 3 PRESERVE-003 trial results show promise, uncertainty around confirmatory Phase 3 enrollment and FDA approval for its oncology drugs could impact potential revenue generation. Furthermore, BioNTech's reliance on its Pfizer-partnered covid vaccine for commercial success could pose a risk, as alternative brands with greater efficacy or ease of use may emerge. With multiple factors potentially hindering revenue projections, investors should approach BioNTech's stock with caution.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares